A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells

Cancer Research

Volumn 63, Issue 8, 2003, Pages 1834-1837

  Liu, Tie Fu ^a   Cohen, Kimberley A ^a   Ramage, Jason G ^a   Willingham, Mark C ^a   Thorburn, Andrew M ^a   Frankel, Arthur E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN EPIDERMAL GROWTH FACTOR FUSION PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; THYMIDINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; RADIOASSAY;

BRAIN NEOPLASMS; CARCINOMA, SQUAMOUS CELL; DIPHTHERIA TOXIN; DRUG SCREENING ASSAYS, ANTITUMOR; EPIDERMAL GROWTH FACTOR; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MICROSCOPY, FLUORESCENCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0037447150     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics, 2001. CA Cancer J. Clin., 51: 15-36, 2001.
2. Polednak, A. P., and Flannery, J. T. Brain, other central nervous system, and eye cancer. Cancer (Phila.), 75 (Suppl. 1): 330-337, 1995.
3. Glioma Meta-analysis Trialists (GMT) Group. Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 359: 1011-1018. 2002.
4. Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., and Herman, J. G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med., 343: 1350-1354, 2000.
5. Gaspar, L. E., Fisher, B. J., Macdonald, D. R., LeBer, D. V., Halperin, E. C., Schold, S. C., and Caimcross, J. G. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int. J. Radiat. Oncol. Biol. Phys., 24: 55-57, 1992.
6. Laske, D. W., Youle, R. J., and Oldfield, E. H. Tumor regression with regional distribution of the targeted toxin Tf-CRM107 in patients with malignant brain tumors. Nat. Med., 3: 1362-1368. 1997.
7. Rand, R. W., Kreitman, R. J., Patronas, N., Varricchio, F., Pastan, I., and Puri, R. K. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin. Cancer Res., 6: 2157-2165, 2000.
8. Prados, M. D., Lang, F. F., Stauss, L. C., Fleming, C. K., Aldape, K., Kunwar, S., Yung, W. A., Chang, S. M., Husain, S. R., Gutin, P. H., Raizer, J. J., Piepmeier, J. M., Berger, M., McDermott, M., and Puri, R. K. Intratumoral and intracerebral microin-fusion of IL13-PE38QQR cytotoxin: phase I/II study of pre- and post-resection infusions in recurrent resectable malignant glioma. Proc. ASCO, 21: 69b, 2002.
9. Vallera, D. A., Li, C., Jin, N., Panoskaltsis-Mortari, A., and Hall, W. A. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J. Natl. Cancer Inst. (Bethesda), 94: 597-606, 2002.
10. Li, C., Hall, W. A., Jin, N., Todhunter, D. A., Panoskaltsis-Mortari. A., and Vallera, D. A. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng., 15: 419-427, 2002.
11. Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., and Vogelstein, B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl. Acad. Sci. USA, 84: 6899-6903, 1987.
12. Sauter, G., Maeda, T., Waldman, F. M., Davis, R. L., and Feuerstein, B. G. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am. J. Pathol., 148: 1047-1053, 1996.
13. Chakravarti, A., Delaney, M. A., Noll, E., Black, P. M., Loeffler, J. S., Muzikansky, A., and Dyson, N. J. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin. Cancer Res., 7: 2387-2395, 2001.
14. Tang, P., Steck, P. A., and Yung, W. K. The autocrine loop of TGF-alpha/EGFR and brain tumors. J. Neuro-oncol., 35: 303-314, 1997.
15. 389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. Biol. Chem., 266: 21118-21124, 1991.
16. Cohen, K. A., Bissonnette. R., Puri, R. K., and Frankel, A. E. Novel fusion protein therapy of refractory brain tumors. Curr. Pharm. Biotechnol., 4: 39-49, 2003.
17. 389EGF in patients with solid malignancies that express EGF receptors (EGFr). Proc. ASCO, 14: 480, 1995.
18. Engebraaten, O., Hjortland, G. O., Juell, S., Hirschberg, H., and Fodstad, O. Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int. J. Cancer, 97: 846-852, 2002.
19. Zalutsky, M. R. Growth factor receptors as molecular targets for cancer diagnosis and therapy. Q. J. Nucl. Med., 41: 71-77, 1997.
20. Chu, C. T., Everiss, K. D., Wikstrand, C. J., Batra, S. K., Kung, H. J., and Bigner, D. D. Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J., 324: 855-861, 1997.